Elan Corp, plc (ADR) (NYSE:ELN)
CAPS Rating:
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
RSS Headlines
Fool UK
Recs
will show better profitability post spinoff